搜尋結果
美股前瞻 | 三大股指期貨齊漲,今晚三巫日“駕到”
阿思達克財經網· 3 日前1. 6月21日(週五)美股盤前,美股三大股指期貨齊漲。截至發稿,道指期貨漲0.02%,標普500指數期貨漲0.0...
Health Care Roundup: Market Talk
The Wall Street Journal· 3 日前Find insight on Zealand Pharma’s petrelintide shot , Sarepta Therapeutics, EssilorLuxottica, ...
Wall Street futures edge lower ahead of business survey data
Reuters· 3 日前U.S. stock index futures edged lower on Friday as megacap tech and chip stocks lost ground, ...
Weight loss drug contender Zealand Pharma jumps 18% on trial results
CNBC· 3 日前Shares of Denmark's Zealand Pharma popped on Friday, notching a record high after an ...
減肥筆市場未來十年達1000億美元 諾和諾德、禮來兩家瓜分
鉅亨網 via Yahoo財經香港· 3 日前諸如諾和諾德 (NVO-US) 出品的 Wegovy 和禮來公司 (LLY-US) 生產的 Zepbound 這類減肥藥開拓了一個市 ...
Zealand Pharma Shares Jump 17% After Positive Trial Results For Ozempic Competitor
Forbes· 3 日前Shares for Zealand Pharma rose by over 17% on Friday, after the Danish biotech firm announced positive trial results for ...
25 Companies Hiring Now For Fully Remote Jobs In 2024
Forbes· 3 日前Within the United States, the professional, scientific, and computer-related occupations have the highest shares of job ...
《大行》麥格理升康方生物(09926.HK)目標價至64元 評級「跑贏大市」
AASTOCKS via Yahoo財經香港· 3 日前目標價升14%至64元,以反映以上積極的臨床數據和在內地獲批新藥上市申請。 該行認為,合作方美國藥企Summit Therapeutics(SMMT.US)股價今年以來上升204%, ...
NK 細胞是比 CAR-T 更好的癌症療法?
科技新報 TechNews· 3 日前CAR-T(嵌合抗原受體 T 細胞)療法是免疫療法,2017 年首獲美國 FDA 批准治療血癌,是當時重大突破。此法利用病患自己的免疫細胞,改造放大數量後能攻擊癌細胞 ...
US FDA approves expanded use of Sarepta's Duchenne gene therapy
Reuters· 3 日前, opens new tab gene therapy for all patients with Duchenne muscular dystrophy aged four and ...